Domestic pharma giant Cipla has taken the route of applying for a "voluntary license" for Merck's HIV Isentress (a generic raltegravir) saying it is not reaching needy patients in India and is prices exorbitantly.
first published: Apr 4, 2011 12:50 pm
A collection of the most-viewed Moneycontrol videos.

Trump Announces New 10% Global Tariff; Invokes Sections 122, 232 And 301 | Explained

US Supreme Court Rejects Trump Global Tariffs, Rules Emergency Powers Were Exceeded

Jason Oxman on AI, Jobs & Digital Trade | India’s Global Tech Leadership

Live: Nifty unfazed by US-Iran tensions, ends week with gains | Closing Bell
You are already a Moneycontrol Pro user.


